Evidence map›Paper›PMID 18803879›Full record

ArticleBMC cancer2008

Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.

Qing Ji, Xinbao Hao, Yang Meng, Min Zhang, Jeffrey Desano, Daiming Fan, Liang Xu

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
198citing papers in PubMed, 1 pooled it
11.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

198 citing papers in PubMed, 1 synthesis or guideline pooled it, 392 citations in OpenAlex.

  1. Association between miR34b/c polymorphism rs4938723 and cancer risk: a meta-analysis of 11 studies including 6169 cases and 6337 controls.Medical science monitor : international medical journal of experimental and clinical research · 2014
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Evidence for a TMAO-HULC-miRNA regulatory axis in colorectal cancer cells.International journal of molecular and cellular medicine · 2025
    Article
  8. Review
  9. miRNAs in HCC, pathogenesis, and targets.Hepatology (Baltimore, Md.) · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. miRNA: A Promising Therapeutic Target in Cancer.International journal of molecular sciences · 2022
    Review

138 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Qing JiState Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, PR China. qingj@umich.edu
Xinbao Hao
Yang Meng
Min Zhang
Jeffrey Desano
Daiming Fan
Liang Xu
University of Michigan–Ann Arbor · USAir Force Medical University · CNXijing Hospital · CN

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Scott Michael Schuetze · 1988 to 2026
$178.2M
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectorsR01CA121830 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI XU, LIANG · 2006 to 2010
$1.9M
Tumor targeted RNAi by novel nanovectors for molecular therapy of prostate cancerR21CA128220 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI XU, LIANG · 2007 to 2008
$225k
NCI NIH HHS P30 CA046592NCI NIH HHS P30 CA46592NCI NIH HHS R01 CA121830NCI NIH HHS R01 CA121830-01NCI NIH HHS R21 CA128220
6 · The paper itself

Abstract

backgroundMicroRNAs (miRNAs), some of which function as oncogenes or tumor suppressor genes, are involved in carcinogenesis via regulating cell proliferation and/or cell death. MicroRNA miR-34 was recently found to be a direct target of p53, functioning downstream of the p53 pathway as a tumor suppressor. miR-34 targets Notch, HMGA2, and Bcl-2, genes involved in the self-renewal and survival of cancer stem cells. The role of miR-34 in gastric cancer has not been reported previously. In this study, we examined the effects of miR-34 restoration on p53-mutant human gastric cancer cells and potential target gene expression.

methodsHuman gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral miR-34-MIF expression system, and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter. Potential target gene expression was assessed by Western blot for proteins, and by quantitative real-time RT-PCR for mRNAs. The effects of miR-34 restoration were assessed by cell growth assay, cell cycle analysis, caspase-3 activation, and cytotoxicity assay, as well as by tumorsphere formation and growth.

resultsHuman gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2, Notch, and HMGA2. Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were functional and confirmed that Bcl-2 is a direct target of miR-34. Restoration of miR-34 chemosensitized Kato III cells with a high level of Bcl-2, but not MKN-45 cells with a low level of Bcl-2. miR-34 impaired cell growth, accumulated the cells in G1 phase, increased caspase-3 activation, and, more significantly, inhibited tumorsphere formation and growth.

conclusionOur results demonstrate that in p53-deficient human gastric cancer cells, restoration of functional miR-34 inhibits cell growth and induces chemosensitization and apoptosis, indicating that miR-34 may restore p53 function. Restoration of miR-34 inhibits tumorsphere formation and growth, which is reported to be correlated to the self-renewal of cancer stem cells. The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2, Notch, and HMGA2, indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making. Our study suggests that restoration of the tumor suppressor miR-34 may provide a novel molecular therapy for p53-mutant gastric cancer.

Indexed as

Cell ProliferationAntineoplastic AgentsCaspase 3Cell Line, TumorDrug Resistance, NeoplasmG1 PhaseGene Expression Regulation, NeoplasticGenes, bcl-2Genes, Tumor SuppressorHumansMicroRNAsSpheroids, CellularStomach NeoplasmsTransfectionTumor Suppressor Protein p53Antineoplastic AgentsCaspase 3MicroRNAsMIRN34 microRNA, humanTumor Suppressor Protein p53

Identifiers

PMID18803879
PMCPMC2564978
OpenAlexW2138343959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.